Moderna: Spikevax approved for children at increased risk

Published: 2025-07-10 09:32:25 ET MRNA

Published on 07/10/2025 at 09:32

Moderna announces that the US FDA has approved the supplemental biologics license application (sBLA) for its Spikevax vaccine in children aged six months to 11 years who are at increased risk of COVID-19.The biotechnology group notes that its COVID-19 vaccine was previously available for pediatric populations under an Emergency Use Authorization (EUA).COVID-19 continues to pose a significant potential threat to children, particularly those with underlying health conditions, it said.Spikevax is now approved for everyone aged 65 and older, and for those aged six months to 64 with an increased risk. The updated vaccine is expected to be available in the United States for the 2025-26 respiratory virus season.Copyright (c) 2025 CercleFinance.com - All rights reserved.